Please login to the form below

Not currently logged in
Email:
Password:

CAR-T therapy

This page shows the latest CAR-T therapy news and features for those working in and with pharma, biotech and healthcare.

Kite’s CAR-T therapy Yescarta shows positive results in second-line lymphoma study

Kite’s CAR-T therapy Yescarta shows positive results in second-line lymphoma study

Gilead company Kite has unveiled positive results for its CAR-T therapy Yescarta in the second-line setting for relapsed or refractory large B-cell lymphoma (LBCL).  . ... The CAR-T therapy also met key secondary endpoints of complete response rate and

Latest news

More from news
Approximately 19 fully matching, plus 97 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 1 fully matching, plus 25 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • In the precision medicine era, the line between products and services is blurred

    In a nutshell, CAR-T therapy involves extracting T-cells (a type of white blood cells that play a key role in immune response) from the patient, genetically engineering them to ... However, due to its novelty, it was difficult to access patients who have

  • The impossible launch

    SpaceX is inspiring people in a way that NASA hasn’t managed in over 30 years. ... Today’s therapy advances, such as CAR-T and gene therapy, are just as exciting and will help shape our world in the years to come.

  • Understanding the evolving CAR-T market

    In August 2017, Novartis made history after receiving FDA approval for Kymriah, the world’s first chimeric antigen receptor T-cell (CAR-T) therapy. ... Today, the CAR-T market is expected to increase at an annual rate of 30% until 2030.

  • Precision paediatrics: Treating patients with CAR-T

    Here, we discuss the story behind CAR-T therapy and the steps being taken to ensure more patients can access it. ... It’s an exciting time for CAR-T therapy. SA: It’s an integrated, holistic approach.

  • Highlights in haematologic malignancy from ASH 2018

    The spotlight shone on Chimeric Antigen Receptor(CAR) T-cell therapy; a transformative approach where the patient’s T cells are harvested and re-engineered to recognise antigens expressed by the ... A reduced risk of relapse was also seen when

More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
The Good Ideas Group

Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....